

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

October 14, 2017

BSE Limited

1st Floor, P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051

Re.: **Press Release**

Dear Sir / Madam,

We enclose herewith a copy of press release dated October 14, 2017 titled "Zydus receives final approval from the USFDA for Allopurinol Tablets USP".


The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**



UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above

Zydus receives final approval from the USFDA for Allopurinol Tablets USP

Ahmedabad, 14 October 2017

Zydus Cadila has received the final approval from the USFDA to market Allopurinol Tablets USP, 100 mg and 300 mg. The drug is indicated in the management of patients with gout and patients with cancer who are receiving therapy that causes elevations of serum and urinary uric acid levels. It will be manufactured at the group's formulations manufacturing facility at Baddi.

The sales of Allopurinol Tablets USP are estimated at \$141.2 million. *Source: IMS Health, IMS National Sales Perspective Audit, MAT August 2017, extracted October 2017.*

The group now has more than 160 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
